EPIX Pharmaceuticals Expands Scientific Advisory Board.Appointments Mark Expansion in CNS See Continuous net settlement.
See continuous net settlement (CNS). ; Added Expertise in Immunological, Inflammatory and Infectious Diseases
LEXINGTON, Mass. -- EPIX EPIX Emergency Preparedness Information Exchange
EPIX Enhanced Performance unIX
EPIX European Property Stock Index Pharmaceuticals, Inc. (NASDAQ NASDAQ
in full National Association of Securities Dealers Automated Quotations
U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : EPIX) today announced the appointments of Charles A. Dinarello Charles A. Dinarello is a professor of medicine currently at the University of Colorado at Denver. He is an expert on inflammatory cytokines, specifically Interleukin 1. Dinarello is considered one of the founding fathers of cytokines having purified and cloned interleukin-1. , M.D., professor of medicine at the University of Colorado University of Colorado may refer to:
Dr. Dinarello and Dr. Roberts join the existing members of the EPIX SAB, including Tamas Bartfai, Ph.D., chairman of the EPIX SAB and chairman of the department of molecular and integrative neurosciences and director of the Harold L. Dorris Neurological Institute at The Scripps Research Institute in La Jolla, California; Elliot S. Gershon, M.D., professor of psychiatry and human genetics, the University of Chicago in Chicago, Illinois; and Eric J. Nestler, M.D., Ph.D., professor and chairman of the department of psychiatry at the University of Texas Southwestern Medical Center in Dallas, Texas.
"We are pleased to welcome Charles and Edward to the EPIX SAB and are fortunate to have the experience and knowledge of all five of these accomplished thought-leaders informing our current and future discovery and development efforts," said Sharon Shacham, Ph.D., vice president of product development. "We believe the SAB is a vital strategic asset for our continued growth, and we look forward to further collaboration with the members of our SAB as we continue to pursue new discovery targets and develop our four lead therapeutic product candidates."
Tamas Bartfai, Ph.D., chairman of the EPIX SAB, further commented, "We look forward to working with Charles and Edward on the EPIX SAB. We are pleased with the progress EPIX has made in advancing the clinical development of the therapeutic product candidates in their pipeline and we look forward to working with EPIX management to help guide their continued drug discovery efforts."
About the EPIX SAB
Tamas Bartfai, Ph.D.
Dr. Bartfai is chairman of the department of molecular and integrative neurosciences and director of the Harold L. Dorris Neurological Institute at The Scripps Research Institute in La Jolla, California. Dr. Bartfai is a member of the Nobel Prize committee. He has also served as a fellow at the Neurosciences Institute, as well as secretary of the National Committee for Biochemistry and Molecular Biology of the Royal Swedish Academy of Sciences The Royal Swedish Academy of Sciences or Kungliga Vetenskapsakademien is one of the Royal Academies of Sweden. The Academy is an independent, non-governmental scientific organization which acts to promote the sciences, primarily the natural sciences and mathematics. . He is a member of Academia Europae and an AAAS AAAS American Association for the Advancement of Science. fellow.
Dr. Bartfai has led seminars and lectures around the world, from Yale University and Harvard University in the United States to Tel Aviv University Tel Aviv University (TAU, אוניברסיטת תל־אביב, את"א) is Israel's largest on-site university. in Israel, the University of Tokyo “Todai” redirects here. For the restaurant called Todai, see Todai (restaurant).
The University of Tokyo (東京大学 , National University of Singapore The National University of Singapore (Abbreviation: NUS) is Singapore's oldest university. It is the largest university in the country in terms of student enrollment and curriculum offered. , and many more. Dr. Bartfai earned is Ph.D. in biochemistry from Stockholm University.
Charles A. Dinarello, M.D.
Dr. Dinarello is a professor of medicine at the University of Colorado School of Medicine and is a member of the U.S. National Academy of Sciences. Until 1996, Dr. Dinarello was professor of medicine and pediatrics at Tufts University School of Medicine The Tufts University School of Medicine is one of the eight schools that comprise Tufts University. Located on the university's health sciences campus in the Chinatown district of Boston, Massachusetts, the medical school has clinical affiliations with thousands of doctors and and a staff physician at the New England Medical Center Hospital in Boston. Dr. Dinarello received his medical degree from Yale University and his clinical training at the Massachusetts General Hospital Massachusetts General Hospital Health care The major teaching hospital for Harvard Medical School, widely regarded as one of the best health care centers in the world .
Dr. Dinarello served as a member of the Board of Scientific Advisors of the National Institutes of Allergy and Infectious Diseases. He presently serves on the editorial board of several scientific journals including PNAS PNAS Proceedings of the National Academy of Sciences
PNAS Phosphate:Na + Symporter
PNAS Pensacola Naval Air Station
PNAS Philippine National Airsoft Society . Dinarello has published over 450 original research articles on cytokines, particularly interleukin-1. The Institute for Scientific Information listed Dr. Dinarello as the world's 4th most-cited scientist during the 20 years 1983-2002.
Dr. Dinrello was vice president of the American Society of Clinical Investigation (1989-1990) and president of the International Cytokine Society (1995-1996). Dr. Dinarello is the recipient of several awards for his contributions to the field of infectious diseases and cytokines. In addition to his active academic research career, Dr. Dinarello serves on the Board of Governors of both the Weizmann Institute and Ben Gurion University.
Elliot S. Gershon, M.D.
Elliot S. Gershon, MD, is Foundations Fund Professor of Psychiatry and Human Genetics at the University of Chicago. Dr. Gershon successfully directed several pedigree collection in Bipolar disorder and Schizophrenia, and is known for his contributions to diagnostic definitions and methodology in clinical study of these disorders. His laboratory's findings in linkage and association analysis in Bipolar disorder are widely recognized as among the most significant in the field. He has been a Principle Investigator on multiple NIH "Not invented here." See digispeak.
NIH - The United States National Institutes of Health. grants, including three current R01 grants.
After receiving his bachelor's and medical degrees from Harvard University, Dr. Gershon became a teaching fellow at Harvard Medical School Harvard Medical School (HMS) is one of the graduate schools of Harvard University. It is a prestigious American medical school located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts. , and served his residency at Massachusetts Mental Health Center in Boston. Dr. Gershon serves on numerous advisory boards in the area of psychiatric disorders, as well as on the editorial boards for various psychiatric and pharmacologic publications. He has contributed to countless medical journals and other publications, and holds medical licenses in both the U.S. and Israel.
Eric J. Nestler, M.D., Ph.D.
Dr. Nestler currently serves as the Lou and Ellen McGinley Distinguished Professor and chair of the department of psychiatry at the University of Texas Southwestern Medical Center in Dallas. Dr. Nestler's research focuses on understanding the biochemical pathways that cause depression and drug addiction.
After receiving his bachelor, Ph.D. and M.D. degrees from Yale University, Dr. Nestler joined the faculty there as a professor of psychiatry and neurobiology Neurobiology
Study of the development and function of the nervous system, with emphasis on how nerve cells generate and control behavior. The major goal of neurobiology is to explain at the molecular level how nerve cells differentiate and develop their from 1987 to 1992. He also served as the director of molecular psychiatry research facilities at Yale before joining the University of Texas Southwestern Medical Center. Dr. Nestler serves on the editorial boards of numerous neuroscience and psychiatric journals. Dr. Nestler serves on the SABs of the National Alliance for Research in Schizophrenia and Depression, and the National Alliance for Autism Research The National Alliance for Autism Research (NAAR), based in Princeton, New Jersey, was a non-profit advocacy organization, founded by parents of children with autism concerned about the limited funding available for research. and is a past member of the Board of Scientific Counselors of the National Institute on Drug Abuse The National Institute on Drug Abuse (NIDA) is a United States federal-government research institute whose mission is to "lead the Nation in bringing the power of science to bear on drug abuse and addiction. .
Edward Roberts, Ph.D.
Dr. Roberts is a professor of translational chemistry and medicine at The Scripps Research Institute. Prior to his joining The Scripps Research Institute, Dr. Roberts served as senior vice president and chief scientific officer for Kemia, Inc., where he lead the company's drug discovery efforts. Previously, Dr. Roberts was with F. Hoffmann-La Roche Ltd. in Basel, Switzerland, where he was senior vice-president and head of discovery chemistry. Dr. Roberts was responsible for drug discovery chemistry done in all the therapeutic areas represented at the corporate headquarters, which included diseases of the central nervous system as well as the vascular and metabolic therapeutic areas.
Dr. Roberts served as director of AstraZeneca Research and Development in Montreal, Canada, where he helped form a new research group in the field of peripheral and central nervous system diseases. After 2 years at the University College of Wales Wales, Welsh Cymru, western peninsula and political division (principality) of Great Britain (1991 pop. 2,798,200), 8,016 sq mi (20,761 sq km), west of England; politically united with England since 1536. The capital is Cardiff. , Cardiff, Dr. Roberts joined the Parke-Davis Neuroscience Research Centre at Addenbrooks Hospital in Cambridge, England. Dr. Roberts received a Bachelor of Science Noun 1. Bachelor of Science - a bachelor's degree in science
bachelor's degree, baccalaureate - an academic degree conferred on someone who has successfully completed undergraduate studies degree with Honors in biochemistry from the University of Sussex and his Ph.D. in organic chemistry from the University of Newcastle-upon-Tyne. Dr. Roberts has authored more than 50 articles in major science journals, has presented papers at leading chemistry conferences around the world, and holds over 20 issued patents on discoveries.
About EPIX Pharmaceuticals
EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has five internally-discovered therapeutic and imaging drug candidates currently in clinical trials targeting conditions such as depression, Alzheimer's disease, cardiovascular disease and obesity. These drug candidates include PRX-08066 in Phase 2a clinical development for pulmonary hypertension associated with chronic obstructive pulmonary disease chronic obstructive pulmonary disease
n. Abbr. COPD
A chronic lung disease, such as asthma or emphysema, in which breathing becomes slowed or forced. , PRX-03140 which is in a Phase 2a clinical trial in Alzheimer's disease, PRX-00023 which is being developed to treat major depression, and PRX-07034, which is in Phase 1 clinical development for the treatment of obesity and cognitive impairment. The company also has a blood-pool imaging agent (Vasovist[TM]) approved in 30 countries and marketed in Europe. EPIX also has collaborations with leading organizations, including GlaxoSmithKline, Amgen, Cystic Fibrosis Foundation The Cystic Fibrosis Foundation (CFF) is a non-profit organization in the United States established to provide the means to cure and control cystic fibrosis. The Foundation provides information about cystic fibrosis (CF) and finances CF research that aims to improve the Therapeutics, and Bayer Schering Pharma, AG Germany. For more information about EPIX, please visit the company's website at www.epixpharma.com.